{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T18:23:24Z","timestamp":1770143004658,"version":"3.49.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T00:00:00Z","timestamp":1721001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T00:00:00Z","timestamp":1721001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s13555-024-01217-w","type":"journal-article","created":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T16:02:19Z","timestamp":1721059339000},"page":"2181-2193","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Impact of Lebrikizumab on Vaccine-Induced Immune Responses: Results from a Phase\u00a03 Study in Adult Patients with Moderate-to-Severe Atopic Dermatitis"],"prefix":"10.1007","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct04626297","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5586-0677","authenticated-orcid":false,"given":"Jennifer","family":"Soung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivian","family":"Laquer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hany","family":"Elmaraghy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaoran","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Lucia Buziqui","family":"Piruzeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangeline","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Garcia Gil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abel D.","family":"Jarell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,15]]},"reference":[{"issue":"3","key":"1217_CR1","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.jid.2018.08.028","volume":"139","author":"ZC Chiesa Fuxench","year":"2019","unstructured":"Chiesa Fuxench ZC, Block JK, Boguniewicz M, et al. Atopic dermatitis in America study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population. J Invest Dermatol. 2019;139(3):583\u201390.","journal-title":"J Invest Dermatol"},{"issue":"4","key":"1217_CR2","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/j.1365-2222.2007.02679.x","volume":"37","author":"J Harrop","year":"2007","unstructured":"Harrop J, Chinn S, Verlato G, et al. Eczema, atopy and allergen exposure in adults: a population-based study. Clin Exp Allergy. 2007;37(4):526\u201335.","journal-title":"Clin Exp Allergy"},{"issue":"5","key":"1217_CR3","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.clindermatol.2018.05.007","volume":"36","author":"R Sacotte","year":"2018","unstructured":"Sacotte R, Silverberg JI. Epidemiology of adult atopic dermatitis. Clin Dermatol. 2018;36(5):595\u2013605.","journal-title":"Clin Dermatol"},{"issue":"9","key":"1217_CR4","first-page":"936","volume":"11","author":"HA Hadi","year":"2021","unstructured":"Hadi HA, Tarmizi AI, Khalid KA, Gajd\u00e1cs M, Aslam A, Jamshed S. The epidemiology and global burden of atopic dermatitis: a narrative review. Life (Basel). 2021;11(9):936.","journal-title":"Life (Basel)"},{"issue":"1","key":"1217_CR5","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jaad.2018.07.048","volume":"80","author":"A Blauvelt","year":"2019","unstructured":"Blauvelt A, Simpson EL, Tyring SK, et al. Dupilumab does not affect correlates of vaccine-induced immunity: a randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis. J Am Acad Dermatol. 2019;80(1):158\u2013167.e1.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1217_CR6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jaad.2021.03.032","volume":"85","author":"JF Merola","year":"2021","unstructured":"Merola JF, Bagel J, Almgren P, et al. Tralokinumab does not impact vaccine-induced immune responses: results from a 30-week, randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis. J Am Acad Dermatol. 2021;85(1):71\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"1217_CR7","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/S1473-3099(18)30400-6","volume":"18","author":"WH Chen","year":"2018","unstructured":"Chen WH, Neuzil KM, Boyce CR, et al. Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase\u00a01, single-centre, double-blind, randomised, controlled study. Lancet Infect Dis. 2018;18(10):1088\u201396.","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"1217_CR8","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1093\/bjd\/ljad022","volume":"188","author":"A Blauvelt","year":"2023","unstructured":"Blauvelt A, Thyssen JP, Guttman-Yassky E, et al. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase\u00a0III trials. Br J Dermatol. 2023;188(6):740\u20138.","journal-title":"Br J Dermatol"},{"issue":"12","key":"1217_CR9","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1056\/NEJMoa2206714","volume":"388","author":"JI Silverberg","year":"2023","unstructured":"Silverberg JI, Guttman-Yassky E, Tha\u00e7i D, et al. Two phase\u00a03 trials of lebrikizumab for moderate-to-severe atopic dermatitis. N Engl J Med. 2023;388(12):1080\u201391.","journal-title":"N Engl J Med"},{"issue":"3","key":"1217_CR10","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/bjd.19574","volume":"184","author":"A Wollenberg","year":"2021","unstructured":"Wollenberg A, Blauvelt A, Guttman-Yassky E, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase\u00a0III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184(3):437\u201349.","journal-title":"Br J Dermatol"},{"issue":"24","key":"1217_CR11","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase\u00a03 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335\u201348.","journal-title":"N Engl J Med"},{"issue":"12","key":"1217_CR12","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1136\/annrheumdis-2015-207841","volume":"74","author":"KL Winthrop","year":"2015","unstructured":"Winthrop KL, Novosad SA, Baddley JW, et al. Opportunistic infections and biologic therapies in immunemediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance. Ann Rheum Dis. 2015;74(12):2107\u201316.","journal-title":"Ann Rheum Dis"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01217-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01217-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01217-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T14:30:15Z","timestamp":1724077815000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01217-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,15]]},"references-count":12,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["1217"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01217-w","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,15]]},"assertion":[{"value":"19 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Hany Elmaraghty, Chaoran Hu, Maria Lucia Buziqui Piruzeli, and Evangeline Pierce, are all employees and shareholders of Eli Lilly and Company. Esther Garcia Gil is an employee and shareholder of Almirall. Jennifer Soung has received honoraria or research funds Amgen, Eli Lilly, Abbvie, Pfizer, National Psoriasis Foundation, LEO, Regeneron, Sanofi, Arcutis, Dermavant, Novartis. Joseph Merola declares that he has acted as a consultant for AbbVie, Biogen, Celgene, Dermavant, Eli Lilly, Janssen, Leo Pharma, Novartis, Pfizer and UCB. Angela Moore has received honoraria or research funds from Arcutis, Abbvie, Aclaris, Almirall, Bayer, Bristol Meyers Squibb, Cara Therapeutics, Galderma, Incyte, Janssen, Eli Lilly and Company, Pfizer, Rapt, Regeneron, Sanofi, and Therapeutics. Vivian Laquer conducts research for Abbvie, Acelyrin, Acrotech, Amgen, Argenx, Arcutis, Aslan, Biofrontera, Bristol Meyers Squibb, Cara, Dermavant, Eli Lilly and Company, Galderma, Horizon Therapeutics, Incyte, Janssen, Leo, Novartis, Padagis, Pfizer, Q32, Rapt, Sun, UCB and Ventyx. Abell Jarell has received honoraria and\/or research grants from AbbVie, Almirall, Alumis, Apogee Therapeutics, Arcutis Biotherapeutics, Asana Biosciences, BMS, Castle Biosciences, Concert Pharmaceuticals, Dermavant Sciences, Dermira, Eli Lilly and Company, Foamix Pharmaceuticals, Galderma, Incyte Corporation, Janssen Biotech, Leo Pharma, Novartis, Pfizer, Takeda Pharmaceuticals, UCB, and Vivex Biomedical.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The trials were conducted in accordance with ethical principles of the Declaration of Helsinki and Good Clinical Practice guidelines, and the research protocols were approved by each center\u2019s institutional review board or ethics committee. All patients provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}